Homology Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
QTTB$9.33-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| For the Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(112,961) | $(5,005) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 578 | 1,293 |
| Noncash lease expense | 2,065 | 1,306 |
| Loss from equity method investment | 25,881 | 5,488 |
| Stock-based compensation expense | 7,324 | 13,054 |
| Accretion of discount on short-term investments | (2,948) | (1,947) |
| Non-cash gain on lease termination | (8,866) | — |
| (Gain) loss on disposal of property and equipment | (94) | 49 |
| Gain on sale of business | — | (131,249) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,988 | 840 |
| Accounts payable | 2,090 | (981) |
| Accrued expenses and other liabilities | (11,686) | 7,418 |
| Deferred revenue | (1,156) | (3,208) |
| Operating lease liabilities | (1,445) | (719) |
| Net cash used in operating activities | (96,230) | (113,661) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (73,240) | (157,460) |
| Maturities of short-term investments | 174,240 | 65,461 |
| Proceeds from sale of business | — | 130,000 |
| Proceeds from sale of property and equipment | 554 | — |
| Purchases of property and equipment | (228) | (1,285) |
| Net cash provided by investing activities | 101,326 | 36,716 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 168 | 595 |
| Proceeds from issuance of common stock from option exercises | 16 | 1 |
| Net cash provided by financing activities | 184 | 596 |
| Net change in cash, cash equivalents and restricted cash | 5,280 | (76,349) |
| Cash, cash equivalents and restricted cash, beginning of period | 33,986 | 110,335 |
| Cash, cash equivalents and restricted cash, end of period | $39,266 | $33,986 |
| Supplemental disclosures of noncash investing and financing activities: | ||
| Lease liability settled through termination of lease | $28,338 | $— |
| Lease liability obtained in exchange for right-of-use asset | $1,625 | $— |
| Cash paid for income taxes | $— | $720 |
| Unrealized gain (loss) on available for sale securities, net | $399 | $(397) |
| Property and equipment additions included in accrued expenses and other liabilities | $— | $8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.